Christine Fox Sells 19,388 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Limited (NYSE:TEVA) EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at $744,034.48. The trade was a 30.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock traded up $0.05 during midday trading on Thursday, hitting $17.08. 5,419,790 shares of the company were exchanged, compared to its average volume of 9,216,287. Teva Pharmaceutical Industries Limited has a fifty-two week low of $9.35 and a fifty-two week high of $19.31. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The firm has a market capitalization of $19.35 billion, a PE ratio of -20.03, a price-to-earnings-growth ratio of 1.31 and a beta of 0.87. The business has a fifty day simple moving average of $17.72 and a two-hundred day simple moving average of $17.30.

Analyst Ratings Changes

A number of equities analysts have recently commented on TEVA shares. Barclays lifted their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Finally, UBS Group upped their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $19.67.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Institutional investors have recently bought and sold shares of the company. Coronation Fund Managers Ltd. purchased a new position in shares of Teva Pharmaceutical Industries during the second quarter worth about $1,334,000. Point72 Asset Management L.P. lifted its position in shares of Teva Pharmaceutical Industries by 38.0% during the second quarter. Point72 Asset Management L.P. now owns 1,319,217 shares of the company’s stock worth $21,437,000 after purchasing an additional 363,217 shares in the last quarter. Lighthouse Investment Partners LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $6,825,000. Ritholtz Wealth Management lifted its holdings in shares of Teva Pharmaceutical Industries by 269.5% during the 3rd quarter. Ritholtz Wealth Management now owns 41,643 shares of the company’s stock valued at $750,000 after buying an additional 30,374 shares during the last quarter. Finally, Diversify Wealth Management LLC bought a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $640,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.